核苷(酸)类似物治疗乙型肝炎病毒脱氧核糖核酸阳性且丙氨酸转氨酶正常的患者:开放标签单中心随机平行对照试验方案
该方案为单中心、开放标签、随机平行对照试验,计划纳入约300例HBeAg阴性、ALT正常且HBV DNA阳性的慢性乙型肝炎患者,按血清HBV DNA水平分层后1:1随机分配接受抗病毒治疗或仅定期检查,随访96周,主要结局为病毒学应答率、血清HBV前基因组RNA水平变化及健康相关生活质量评分变化。
要点
- 针对HBeAg阴性、ALT正常且HBV DNA阳性的慢性乙型肝炎患者,抗病毒治疗仍存争议。
- 计划纳入约300例患者,按HBV DNA<2000 vs ≥2000 IU/ml分层后1:1随机分组。
- 主要结局包括病毒学应答率、HBV前基因组RNA水平变化及健康相关生活质量评分变化。
核心结论
- 该试验旨在为HBeAg阴性、ALT正常且HBV DNA阳性的慢性乙型肝炎患者(包括非活动性携带期和灰区)的最佳临床管理提供高质量直接证据。
研究设计与样本
- 单中心、开放标签、随机平行对照试验,随访96周,计划在中国四川大学华西医院招募约300例患者。
- 纳入患者按血清HBV DNA水平(<2000 vs ≥2000 IU/ml)分层后,以1:1比例随机分配接受抗病毒治疗(治疗组)或仅定期检查(对照组)。
主要发现
- 主要结局为病毒学应答率、血清HBV前基因组RNA水平变化及健康相关生活质量评分变化。
- 该试验聚焦HBeAg阴性且ALT正常的患者,包括非活动性携带期和灰区,其抗病毒治疗仍存争议。
- 引入健康相关生活质量量表,以在病毒学应答和不良肝脏事件之外全面评估抗病毒治疗的获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Direct high-quality evidence remains absent on the benefits of HBeAg-negative chronic hepatitis B patients (CHB) with normal alanine transaminase (ALT) and positive HBV DNA after nucleos(t)ide analogs (NAs) treatment. METHODS: This is a single-center, open-label, randomized parallel controlled trial with a follow-up duration of 96 weeks. An estimated 300 patients will be recruited at West China Hospital of Sichuan University, China. After stratified by serum HBV DNA (< 2000 vs. ≥ 2000 IU/ml), eligible patients will be randomized (allocation ratio 1:1) to receive either antiviral therapy (the treatment group) or regular examination alone (the control group). The primary outcomes are rates of virological response and changes in the levels of serum HBV pregenomic RNA (pgRNA) and scores of health-related qualities of life. DISCUSSION: This randomized controlled trial focuses on HBeAg-negative patients with normal ALT, including those of the inactive carrier phase and the grey zone, whose antiviral treatment remains controversial. Additionally, a health-related quality of life scale is introduced to comprehensively estimate the benefit of antiviral treatment apart from virological response and adverse liver events. Meaningfully, the study findings will provide high-quality and direct evidence for optimal clinical management in such populations. TRIAL REGISTRATION: This trial was registered with the Chinese Clinical Trial Registry (ChiCTR2300069391) on 15 March 2023.
引用
- Zhou J, Wang FD, Li LQ, et al. Nucleos(t)ide analogs to treat patients with positive hepatitis B virus deoxyribonucleic acid and normal alanine transaminase: protocol for an open-label single-center randomized parallel controlled trial. Trials. 2024. PMID: 39363218. doi:10.1186/s13063-024-08433-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。